保尔佳对原发性肝癌患者sIL-2R、IL-6、TNFα的影响及促进肝癌细胞凋亡的初步研究

The Influence of Polyerga on IL 6 SIL 2R TNFα and Its Booster Effect to Apoptosis Effect of Hepatic Cancer Cells in Patients with Primary Hepatocellular Carcinoma

对２０例原发性肝癌患者（大剂量组１０例、小剂量组１０例）临床应用保尔佳１周，用ＥＬＩＳＡ法检测治疗组用药前后外周血及用药后门静脉血的ｓＩＬ－２Ｒ，ＩＬ－６，ＴＮＦα的水平变化及用末端转移酶标记法（ＴＵＮＥＬ法）检测治疗组肝癌细胞的凋亡情况，与未治疗组、正常对照组相比。结果表明，治疗组外周血ｓＩＬ－２Ｒ水平明显下降（大剂量组Ｐ＜０．０１、小剂量组Ｐ＜０．０５），ＩＬ－６水平明显上升（大剂量组Ｐ＜０．０１、小剂量组Ｐ＜０．０５），ＴＮＦα水平有所下降（大剂量组Ｐ＜０．０５、小剂量组Ｐ＞０．０５），治疗组门静脉血与外周血ｓＩＬ－２Ｒ、ＩＬ－６、ＴＮＦα两者间无明显差异（Ｐ＞０．０５）。ＴＵＮＥＬ法检测显示保尔佳能促进肝癌细胞的凋亡（Ｐ＜０．０１，大、小剂量组间Ｐ＞０．０５）。且保尔佳对肝癌患者的血常规、肝功能等无不良影响。保尔佳是一种具有增强机体免疫功能、促进肿瘤细胞凋亡且无明显毒副作用的新型抗癌药物。

Twenty cases of primary hepatocelluar carcinoma(large dosage in 10 small dosage in 10)were treated with Polyerga for one week,and then the peripheral blood and portal vein serum level of IL 6,SIL 2R,TNFα were measured.The apoptosis of hepatocellular carcinoma cells(HCC) were determined by terminal deoxynucleotidyl transferase(TUNEL) and were compared to the normal control group( n =10),and HCC patients ( n =10)without Polyerga.The results showed that the SIL 2R level in peripheral blood decreased significantly (large dosage group P <0.01,small dosage group P <0.05).While the IL 6 level increased prominenely (large dosage group P <0.01,small dosage group P <0.05,but TNFα level decreased(large dosage group P <0,05,small dosage P >0.05).There was no difference of SIL 2R,IL 6,TNFα between peripheral blood and portal vein in the treated group ( P >0.05) .Detection of apoptosis by TUNEL method showed that Polyerga could accelerate the apoptosis of HCC and that it had no untoward effects to the blood routine and liver function of the patient.It is concluded that Polyerga is a new anticancer drug that can enhance the body immunity and accelerate apoptosis of cancer cells.